Winners And Losers Of Q2: Bio-Techne (NASDAQ:TECH) Vs The Rest Of The Research Tools & Consumables Stocks

Avantor (AVTR) raised its full-year revenue and earnings guidance after Q2 2026 results, despite noting softness in Bioscience & Medtech Products. The stock has seen a 15.6% 30-day gain and 62.9% 90-day gain, but long-term returns remain negative. Analysts' consensus price target is $14.56, suggesting a 7% overvaluation, with targets ranging from $12.0 to $19.0. The P/S ratio is 1.6x, lower than industry and peer averages.

Bruker Corporation (BRKR) stock rose 7.62% after strong earnings and guidance. The company's BEST unit partnered with Luvata for superconducting wire production, tying it to fusion and high-field magnet projects. UBS raised its price target to $65 but maintained a Neutral rating, citing mixed growth prospects. BRKR's revenue is $3.44B, but it reported a net loss of $52M and negative free cash flow.

Bruker Corporation (BRKR) stock rose 7.66% on September 16, 2026, driven by positive coverage of its scientific instruments and fusion-related advancements. The company's stock has climbed from the mid-$56s to around $60, with recent closes near $60.02. Bruker's revenue is $3.44B with a 46.4% gross margin, but it reported a quarterly net loss of $52M. UBS initiated coverage with a Neutral rating and a $65 price target, citing optimism around fusion technology and AI-linked semiconductor demand.

Bio-Techne faces a shareholder lawsuit and demand letters challenging its proxy disclosures for the pending acquisition by Merck KGaA. The lawsuit seeks to halt the shareholder vote scheduled for September 23, 2026. Bio-Techne plans to supplement the proxy with additional disclosures on the sale process and financial advisor details, which may impact investor assessment of the deal.

BIO-TECHNE Corp (TECH) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. As previously disclosed, on June 25, 2026, Bio-Techne Corporation, a Minnesota corporation (“ Bio-Techne ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Merck KGaA, Darmstadt, Germany, a German corporation with general par

Bruker Corporation (BRKR) reported Q3 earnings that exceeded expectations, with non-GAAP EPS of $0.45. Shares rose nearly 7% despite cautious guidance. The company faces underlying headwinds but is in transition, according to the report.